Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open. (STRIB-PEP)
Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open.
Sponsor: Fundacion Clinic per a la Recerca Biomédica
A PHASE4 clinical study on HIV, this trial is completed. The trial is conducted by Fundacion Clinic per a la Recerca Biomédica and has accumulated 6 data snapshots since 2015. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
May 2017 — Jun 2018 [monthly]
Completed PHASE4
Status: Unknown Status → Completed
▶ Show 1 earlier version
-
Jan 2017 — May 2017 [monthly]
Unknown Status PHASE4
First recorded
Jun 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fundacion Clinic per a la Recerca Biomédica
For direct contact, visit the study record on ClinicalTrials.gov .